|
Report Date : |
10.01.2014 |
IDENTIFICATION DETAILS
|
Name : |
MEDICAMENTA, INC. |
|
|
|
|
Registered Office : |
No. 40 Mariano Cuenco St., Brgy. Lourdes, Quezon City |
|
|
|
|
Country : |
Philippines |
|
|
|
|
Date of Incorporation : |
1972 |
|
|
|
|
Legal Form : |
Private Company |
|
|
|
|
Line of Business : |
Health & Beauty for drugs & medication; health care
products. |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRAs Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Philippines |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
PHILIPPINES - ECONOMIC OVERVIEW
Philippine GDP growth, which cooled from 7.6% in 2010 to
3.9% in 2011, expanded to 6.6% in 2012 - meeting the government's targeted
6%-7% growth range. The 2012 expansion partly reflected a rebound from
depressed 2011 export and public sector spending levels. The economy has
weathered global economic and financial downturns better than its regional
peers due to minimal exposure to troubled international securities, lower
dependence on exports, relatively resilient domestic consumption, large
remittances from four- to five-million overseas Filipino workers, and a rapidly
expanding business process outsourcing industry. The current account balance
had recorded consecutive surpluses since 2003; international reserves are at
record highs; the banking system is stable; and the stock market was Asia's
second best-performer in 2012. Efforts to improve tax administration and
expenditure management have helped ease the Philippines' tight fiscal situation
and reduce high debt levels. The Philippines received several credit rating
upgrades on its sovereign debt in 2012, and has had little difficulty tapping
domestic and international markets to finance its deficits. Achieving a higher
growth path nevertheless remains a pressing challenge. Economic growth in the
Philippines averaged 4.5% during the MACAPAGAL-ARROYO administration but
poverty worsened during her term. Growth has accelerated under the AQUINO
government, but with limited progress thus far in bringing down unemployment,
which hovers around 7%, and improving the quality of jobs. Underemployment is
nearly 20% and more than 40% of the employed are estimated to be working in the
informal sector. The AQUINO administration has been working to boost the
budgets for education, health, cash transfers to the poor, and other social
spending programs, and is relying on the private sector to help fund major
infrastructure projects under its Public-Private Partnership program. Long term
challenges include reforming governance and the judicial system, building
infrastructure, improving regulatory predictability, and the ease of doing
business, attracting higher levels of local and foreign investments. The
Philippine Constitution and the other laws continue to restrict foreign
ownership in important activities/sectors (such as land ownership and public
utilities).
|
Source
: CIA |
Company: MEDICAMENTA, INC.
Address: No. 40 Mariano Cuenco St., Brgy.
Lourdes, Quezon City
Country: Philippines
Service Type: Normal
Email medicamenta inc
@gmail.com.
We conducted research and verification on MEDICAMENTA, INC. Hereunder
our report, viz:
VERIFICATION WITH
SECURITIES & EXCHANGE COMMISSION (SEC):
MEDICAMENTA, INC.
On-Line verification disclosed that SEC has no financial and
registration documents on file pertaining to subject firm.
VERIFICATION WITH DEPARTMENT OF TRADE
& INDUSTRY (DTI) : MEDICAMENTA, INC.
On-Line verification showed
that MEDICAMENTA INCORPORATED is a DTI registered outfit with address at
6/F, Victoria Building, 11th Avenue, Grace Park, Caloocan City, NCR,
Third Division. The business name is registered as Single Proprietorship. Other
relevant information, not available. Please note that registration of business
name with DTI is renewed every 5 years. Periodic financial and other management
reports are not required with DTI.
As gathered from various
sources, revealed that MEDICAMENTA, INC. is a Filipino-owned pharmaceutical
company. It has been in the importation and distribution business for more than
40 years. Established in l972, in
Malabon, known as MEDICAMENTA PHARMACEUTICALS INC.,and headed by Arnedo C.
Lucas, Sr. In 1975, its business name was amended to MEDICAMENTA, INC. and
relocated to Caloocan City.
Few years later, the
company began to market its first imported product AEKNIL, a paracetamol for
injection, which became their flagship product. Todate, the company expanded its
imported product lines to include ORIMED (Gentamicin Sulfate) for injection;
UNOXIMED (Cefuroxime Sodium) powder for injection; CIPROLAX tablet; and OMED
capsule. The company has signed an agreement with 2 local companies JM
TOLMANN Laboratories, Inc. and Scheele Laboratories Phils. Inc., for
paediatrics and adult vitamin brands, respectively.
Principal Officers are
Ismael M. Cabral, Jr. - President & Chief Operating Officer.
Mobile No.
09228478428
Email juncabral@medicamenta.ph
Renato S. Mendoza -
Sales Manager
Mobile No.
09228137942
Email reymendoza@medicamenta.ph
Mary Lyn Tan - Marketing Assistant
Mobile No.
09228478437
Email mhetan@medicamenta.ph
Business Address 1: No.
40 Mariano Cuenco Street, Brgy. Lourdes, Quezon City
Telephone No.
(632) 749 5189 / (632)
749 9607
Email info@medicamenta.ph
Website www.medicamenta.net
Business Address 2:
6/F Victoria Building, 11th Avenue,
Grace Park, Caloocan City
Telephone No. (632) 364 4122 (Dialed no., busy tone.)
Health & Beauty for drugs
& medication; health care products.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.18 |
|
|
1 |
Rs.102.31 |
|
Euro |
1 |
Rs.84.50 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.